Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra Sohal(University of Cincinnati), Daniel A. Laheru(Bloomberg (United States)), Pelin Cinar(University of California, San Francisco), Philip A. Philip(Wayne State University), Neeha Zaidi(Johns Hopkins University), Christopher H. Crane(Memorial Sloan Kettering Cancer Center), Thierry Conroy(Inserm), Ignacio Garrido‐Laguna(University of Utah), Cassadie Moravek(Pancreatic Cancer Action Network), Mehmet Sitki Copur(CHI Health St. Francis), Tyler Johnson(Palo Alto University), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Vaibhav Sahai(University of Michigan–Ann Arbor), Shubham Pant(The University of Texas MD Anderson Cancer Center), Erin B. Kennedy(Northwell Health), Manish A. Shah(NewYork–Presbyterian Hospital), Hope E. Uronis(Duke Medical Center), Michelle Lau(Saad Specialist Hospital), Smitha Krishnamurthi(Cleveland Clinic)
Cited by 287
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k